Karpus Investment Management’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

Karpus Investment Management’s Portfolio BIOT Stock Details BIOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-25,000	Closed	-$252K	–	461
2022 Q4	$252K	Hold	25,000	–	–	0.01%	395
2022 Q3	$248K	Hold	25,000	–	–	0.01%	460
2022 Q2	$248K	Hold	25,000	–	–	0.01%	459
2022 Q1	$247K	Hold	25,000	–	–	0.01%	408
2021 Q4	$246K	Hold	25,000	–	–	0.01%	346
2021 Q3	$244K	Hold	25,000	–	–	0.01%	279
2021 Q2	$242K	Hold	25,000	–	–	0.01%	274
2021 Q1	$243K	Buy	+25,000	New	+$242K	0.01%	279

Karpus Investment Management's BIOT Position: Q1 2023 in Review

Karpus Investment Management sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q1 2023, closing a stake of 25,000 shares — an estimated $252K sold.

Karpus Investment Management first reported a position in BIOT in Q1 2021 and held it in 8 quarters. The position peaked at $252K in Q4 2022. 0 funds tracked by Wall St. Rank hold BIOT as of Q1 2023.

Karpus Investment Management reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Karpus Investment Management sold 25,000 Biotech Acquisition Company Class A Ordinary Shares shares in Q1 2023, an estimated $252K.
Karpus Investment Management first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q1 2021 and held it in 8 quarters.
Karpus Investment Management's Biotech Acquisition Company Class A Ordinary Shares position peaked at $252K in Q4 2022.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q1 2023.

Based on Karpus Investment Management's 13F filing for Q1 2023, filed 11 May 2023.